TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06328881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive rehabilitation training
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation training
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT05282446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-202
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablet
Study: NCT06307496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Description: Receive links to smoking cessation videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational intervention
Description: Receive NCI's Clearing the Air booklet
Study: NCT06017388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: We will propose a hypnotic induction followed by a suggestion of mystical experience (based on Lynn \& Evans, 2017).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: We will propose the neutral reading of a mystical expetience suggestion (based on Lynn \& Evans, 2017).
Study: NCT06442644

Intervention type: OTHER
Group type: OTHER
Intervention: Live music in the intensive care unit
Description: To test a patient-tailored live music intervention's effect on stress reduction in adult, critically ill patients admitted to the intensive care unit.
Study: NCT05639621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accompaniment
Description: presence of a person freely chosen by the patient, who will escort in a visual and tactile way during the endoscopic procedure
Study: NCT06148675

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention,data collection
Study: NCT05727943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clioquinol
Description: add on clioquinol to concomitant ASM
Study: NCT06038890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate using the veil-sparing technique
Description: Holmium laser enucleation of the prostate using the veil-sparing technique
Study: NCT05660915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermediate approach
Description: The area between superior mesenteric vein and superior mesenteric artery was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard approach
Description: The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
Study: NCT06489665

Intervention type: DIAGNOSTIC_TEST
Intervention: Experimental Intervention
Description: Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device

Intervention type: DIAGNOSTIC_TEST
Intervention: Experimental Intervention
Description: Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
Study: NCT06177236

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cervical cancer screening
Description: The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.
Study: NCT04691297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escape
Description: The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
Study: NCT01539174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT06280456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Powder
Description: 10 mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation with different drainage clamping time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Powder
Description: 10 mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation with different drainage clamping time.
Study: NCT06114563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirulina yogurt
Description: High cardiometabolic risk volunteers will be asked to consume 2 yogurts with spirulina, each containing 2 g spirulina, daily for 8 weeks, without any other change in their dietary habits and physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional yogurt
Description: High cardiometabolic risk volunteers will be asked to consume 2 conventional yogurts (without spirulina), daily for 8 weeks, without any other change in their dietary habits and physical activity.
Study: NCT05264298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIRTUAL
Description: At the time of discharge, stroke survivors in the VIRTUAL arm will receive a package containing an iPad and a remote BP monitoring device that allows transmission of BP to the study team.The first telehealth visit will occur 7-14 days after discharge. Patient will be counseled on the importance of BP monitoring, salt reduction, and the importance of diet and exercise for stroke prevention. Medications, side effects and interactions will be reviewed. The social worker will refer the patient to specific resources according to social needs abd patient will be referred to a primary care provider if they do not have one. Subsequent video visits will be 1-month (30 days +/- 7) , 3 months (90 days +/- 14), and 5 months (150 days +/- 14) days after enrollment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants randomized to standard care will receive an educational packet and a blood pressure monitor prior to hospital discharge. They will be contacted by a social worker to determine if they received their medications and appointments. The stroke practitioner will evaluate the patients at 7-14 days and then follow up according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities. The pharmacist will contact patients at 1-month (30 +/- 7 days) days over the telephone to review BP logs and will make recommendations to their primary care provider to adjust BP medications. Subsequent pharmacist calls will occur monthly until 6 months and recommendations for medication adjustments will be communicated to their primary care provider.
Study: NCT05566002

Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterization
Description: RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).

Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterization
Description: RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
Study: NCT05383651

Intervention type: DEVICE
Intervention: bellavista 1000
Description: observational use of Bellavista 1000 ventilator in adult ventilated patients

Intervention type: DEVICE
Intervention: bellavista 1000 neo
Description: observational use of Bellavista 1000 ventilator in neonatal ventilated patients
Study: NCT05581589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo pelvic lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo radical cystectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given IV
Study: NCT05656807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go NAPSACC Enhanced
Description: Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go NAPSACC
Description: Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
Study: NCT06385314

Intervention type: OTHER
Intervention: Collecting data with oral health related quality of life, dental anxiety and state anxiety
Description: Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.

Intervention type: OTHER
Intervention: Collecting data with oral health related quality of life, dental anxiety and state anxiety
Description: Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.

Intervention type: OTHER
Intervention: Collecting data with oral health related quality of life, dental anxiety and state anxiety
Description: Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.

Intervention type: OTHER
Intervention: Collecting data with oral health related quality of life, dental anxiety and state anxiety
Description: Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.

Intervention type: OTHER
Intervention: Collecting data with oral health related quality of life, dental anxiety and state anxiety
Description: Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.

Intervention type: OTHER
Intervention: Collecting data with oral health related quality of life, dental anxiety and state anxiety
Description: Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.
Study: NCT05359705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DJO 456
Description: Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen 456
Description: Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DJO 464
Description: Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen 464
Description: Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
Study: NCT05658055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Medilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China
Study: NCT05735262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active iTBS
Description: Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active iTBS
Description: Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
Study: NCT05107791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stulln Eyedrops
Description: Stulln eyedrops will be applied to the anterior surface of cornea 3 times a day, 6 days a week. Half of participants (46) also receive accommodative training during the second stage (month) of the study while the rest maintains the Stulln eyedrops intervention.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Thera Tears
Description: The eyedrops will be used in the identical manner as Stulln eyedrops.
Study: NCT06321068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: the usage and dosage should be determined by the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: the usage and dosage should be determined by the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody injection
Description: Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
Study: NCT05575752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high temperature (32℃) group
Description: The exposure group will be exposed to high temperature (32℃) in a chamber for about 2 hours, resting during the whole periods.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: moderate temperature (22℃) group
Description: The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole periods.
Study: NCT05526378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Interventions
Description: Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Interventions
Description: Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Interventions
Description: Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure.
Study: NCT05343364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Oral Tablet
Study: NCT06372249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NOVELOSETM 3490
Description: Soluble tapioca starch from Ingredion.
Study: NCT05156554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 5μg/kg once per day until the count of neutrophil\>0.5×10\^9 /L.
Study: NCT06295640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray
Description: Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Intranasal insulin will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray
Description: Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Placebo spray will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over ten minutes starting at time point -15 minutes on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
Study: NCT04760041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam nebulized
Description: midazolam nebulized

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral solution
Description: midazolam given oral
Study: NCT05093985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation with blood flow restriction
Description: Neuromuscular electrical stimulation with blood flow restriction
Study: NCT04927377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI4DM
Description: Those in the AI4DM intervention arm will receive weekly and bi-weekly calls for six months, access to home and online technology, diabetes-related multimedia educational content, a technology package including a voice-assistive device, wireless glucometer, and wrist-worn activity monitor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-control
Description: Those in the Attention-control Group will receive telecoaching calls at the same frequency of the Intervention Group. Coaching calls will focus on general wellbeing, rather than diabetes-related topics. The Attention-control Group will serve as an untreated comparison group for the Intervention Group.